Virginia-based pediatric care network gains more complete picture of a child's health history, supports early interventions, and enhances patient engagementSolution helps network achieve value-based care objectivesAUSTIN, Texas, June 25, 2025 /PRNewswire/ -- Fortify Children's Health, a Virginia-based pediatric care network, is using Oracle Health Data Intelligence to enhance care for its pediatric population and more effectively manage value-based care contract performance. Using Oracle Health Data Intelli ...

Strategic collaboration expands HealthLynked's focus on interoperability and digital transformation in hospital systems and EMRsNAPLES, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK), a pioneer in healthcare technology and patient engagement, today announced a strategic partnership with Endlink, a healthcare data integration firm led by industry veteran Rubén Viera. This alliance underscores HealthLynked's commitment to building robust partnerships that enhance connectiv ...

Core Insights - Aclarion, Inc. has initiated the first patient enrollment in the CLARITY trial, which aims to evaluate the clinical and economic value of its Nociscan platform in spine surgery for chronic low back pain [1][6] Company Overview - Aclarion is a healthcare technology company that utilizes Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to enhance clinical treatments [5] - The company is focusing on the chronic low back pain market with Nociscan, the first evidence-supported SaaS platform designed to help physicians differentiate between painful and nonpainful discs in the lumbar spine [5] Trial Details - The CLARITY trial is a prospective, randomized multi-center study that will enroll 300 patients scheduled for surgical treatment of 1- or 2-level discogenic low back pain across multiple high-volume sites in the US [2] - The trial will randomize patients in a 1:1 ratio between surgeons who are blinded and unblinded to the Nociscan results, with the primary endpoint being the change in back pain measured on a 100mm VAS scale at 12 months compared to baseline [2][6] - The first patient was enrolled at the Texas Back Institute, which has a strong history in advancing spine care through clinical trial research [2][6] Market Context - Chronic low back pain is a significant global healthcare issue, affecting approximately 266 million people worldwide with degenerative spine disease and low back pain [3] - Aclarion's Nociscan solution aims to objectively quantify chemical biomarkers associated with disc pain, potentially leading to improved surgical outcomes [3][6]

Group 1 - The articles do not provide any specific company or industry insights, focusing instead on disclaimers and disclosures regarding investment advice and performance [1][2][3]

Starlink is expanding into Vietnam with a focus on improving healthcare connectivity.The goal: enable telemedicine, remote consultations, and digital health infrastructure. https://t.co/zVYfzTycQo ...

[Applause] [Music] Hi, I'm Rose Bianini. Um, and today I'm talking about something that is universal yet we avoid talking about which is the way we die. I want to re-imag care to ensure that all of us have what we would consider a good death.We all die. Everyone in this room is going to die. Our loved ones will die.Yet, it's something we don't talk about and we don't prepare for. When Canadians were asked, 96% of them understood that it was important to have some kind of end of life care wishes documented. ...

OMEGA HEALTHCARE INVESTORS INVESTOR PRESENTATION • This presentation may include projections and other "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements relate to future events and expectations and involve unknown risks and uncertainties. Omega's actual results or actions may differ materially from those projected in the forward-looking statements. For a summary of the specific risk factors that could cause results to differ materially f ...

Core Insights - GE HealthCare (GEHC) introduced Flyrcado, an FDA-approved PET imaging agent for myocardial perfusion imaging, at the 2025 SNMMI annual meeting, highlighting its importance in precision cardiac care as cardiovascular disease rates rise globally [1][8] - Flyrcado aims to enhance early disease detection, personalize treatment strategies, and monitor therapy responses, reinforcing GEHC's commitment to improving outcomes for patients at risk of cardiovascular disease [2][6] Product Details - Flyrcado (flurpiridaz F 18) is designed for patients with known or suspected coronary artery disease, featuring a half-life of approximately 110 minutes, which facilitates centralized production and distribution [3] - The agent integrates exercise stress testing with cardiac PET imaging and is compatible with GEHC's Omni Legend PET/CT and other systems, enabling detailed assessments of myocardial perfusion and related conditions [3] Market Position and Coverage - Flyrcado has recently launched in select U.S. markets, receiving CMS pass-through status and a specific HCPCS billing code, with coverage from all seven Medicare Administrative Contractors and over 50% of commercial insurers [4][8] - The expansion of coverage beyond hospital outpatient settings and the establishment of a Flyrcado Support Center for providers indicate a strategic move to enhance accessibility and support for the new imaging agent [4] Financial Performance and Stock Trends - Following the announcement, GEHC shares closed flat at $71.16, with a year-to-date decline of 9%, contrasting with the industry's 4% growth and the S&P 500's 0.8% increase [5][7] - GEHC's market capitalization stands at $32.64 billion, and the company reported a 10.9% earnings surprise in the last quarter, indicating potential for future growth despite current stock performance [7] Strategic Implications - Flyrcado positions GEHC for long-term growth in the high-value molecular imaging market, addressing the rising demand for precision cardiac diagnostics [6] - With broad payer coverage and compatibility with existing systems, Flyrcado is expected to facilitate a shift from SPECT to PET imaging, generating recurring revenue from both radiopharmaceutical sales and imaging hardware [6]

[Music] Hi. Hello. Bonjour. Hold on. Hold on. I'm good. I'm good. I think I just peed myself a little bit, but let's not make it weird. Um, I will say this, my body has impeccable timing, obviously, which you'll understand. This is very coherent with what's about to come. Um, I am here before you today, not as an expert, but as somebody surviving the messiness of midlife. So, it's the wear your PJs kind of messiness in case lunch break was adult for we can all take a quick nap, which it turned out not to be ...

Key Takeaways PFE expects steady 2025 COVID sales but anticipates major LOE losses and IRA headwinds in the future. Medicare Part D changes may cut into sales of key PFE drugs like Vyndaqel, Ibrance, Xtandi and Xeljanz. PFE trades at 7.82x forward earnings, below industry average, with EPS estimates rising for 2025 and 2026.Pfizer (PFE) is likely to encounter several headwinds in the next couple of years that can hurt its sales and profits, the first being declining sales of COVID products, Comirnaty and ...